Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Tamoxifen (TAM) is commonly used to treat estrogen receptor (ER)-positive breast cancer. Despite the remarkable benefits, resistance to TAM presents a serious therapeutic challenge. Since several HOX transcription factors have been proposed as strong candidates in the development of resistance to TAM therapy in breast cancer, we generated an in vitro model of acquired TAM resistance using ER-positive MCF7 breast cancer cells (MCF7-TAMR), and analyzed the expression pattern and epigenetic states of HOX genes. HOXB cluster genes were uniquely up-regulated in MCF7-TAMR cells. Survival analysis of in slico data showed the correlation of high expression of HOXB genes with poor response to TAM in ER-positive breast cancer patients treated with TAM. Gain- and loss-of-function experiments showed that the overexpression of multi HOXB genes in MCF7 renders cancer cells more resistant to TAM, whereas the knockdown restores TAM sensitivity. Furthermore, activation of HOXB genes in MCF7-TAMR was associated with histone modifications, particularly the gain of H3K9ac. These findings imply that the activation of HOXB genes mediate the development of TAM resistance, and represent a target for development of new strategies to prevent or reverse TAM resistance.
Abstract
Tamoxifen (TAM) is commonly used to treat estrogen receptor (ER)-positive breast cancer. Despite the remarkable benefits, resistance to TAM presents a serious therapeutic challenge. Since several HOX transcription factors have been proposed as strong candidates in the development of resistance to TAM therapy in breast cancer, we generated an in vitro model of acquired TAM resistance using ER-positive MCF7 breast cancer cells (MCF7-TAMR), and analyzed the expression pattern and epigenetic states of HOX genes. HOXB cluster genes were uniquely up-regulated in MCF7-TAMR cells. Survival analysis of in slico data showed the correlation of high expression of HOXB genes with poor response to TAM in ER-positive breast cancer patients treated with TAM. Gain- and loss-of-function experiments showed that the overexpression of multi HOXB genes in MCF7 renders cancer cells more resistant to TAM, whereas the knockdown restores TAM sensitivity. Furthermore, activation of HOXB genes in MCF7-TAMR was associated with histone modifications, particularly the gain of H3K9ac. These findings imply that the activation of HOXB genes mediate the development of TAM resistance, and represent a target for development of new strategies to prevent or reverse TAM resistance.
참고문헌 (31)
- Clark GM, "Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer", J Clin Oncol, 2, pp.1102~1109 (1984)[DOI]
- Shang Y, "Cofactor dynamics and sufficiency in estrogen receptorregulated transcription", Cell, 103, pp.843~852 (2000)[DOI]
- Osborne CK, "Tamoxifen in the treatment of breast cancer", N Engl J Med, 339, pp.1609~1618 (1998)[DOI]
- Early Breast Cancer Trialists' Collaborative Group, "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials", Lancet, 365, pp.1687~1717 (2005)[DOI]
- Garcia-Becerra R, "Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance", Int J Mol Sci, 14, pp.108~145 (2012)[DOI]
- Musgrove EA, "Biological determinants of endocrine resistance in breast cancer", Nat Rev Cancer, 9, pp.631~643 (2009)[DOI]
- Wang KC, "Regeneration, repair and remembering identity: the three Rs of Hox gene expression", Trends Cell Biol, 19, pp.268~275 (2009)[DOI]
- Bhatlekar S, "HOX genes and their role in the development of human cancers", J Mol Med (Berl), 92, pp.811~823 (2014)[DOI]
- Shah N, "The Hox genes and their roles in oncogenesis", Nat Rev Cancer, 10, pp.361~371 (2010)[DOI]
- Svingen T, "Altered HOX gene expression in human skin and breast cancer cells", Cancer Biol Ther, 2, pp.518~523 (2003)[DOI]
- Cantile M, "In vivo expression of the whole HOX gene network in human breast cancer", Eur J Cancer, 39, pp.257~264 (2003)[DOI]
- Makiyama K, "Aberrant expression of HOX genes in human invasive breast carcinoma", Oncol Rep, 13, pp.673~679 (2005)
- Morgan R, "Targeting the HOX", PBX dimer in breast cancer, 2012, pp.136, 389~398
- Hur H, "Analysis of HOX gene expression patterns in human breast cancer", Mol Biotechnol, 56, pp.64~71 (2014)[DOI]
- Jin K, "HOX genes: Major actors in resistance to selective endocrine response modifiers", Biochim Biophys Acta, 1865, pp.105~110 (2016)
- Lee JY, "HOXB5 promotes the proliferation and invasion of breast cancer cells", Int J Biol Sci, 11, pp.701~711 (2015)[DOI]
- Jin K, "The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway", Proc Natl Acad Sci U S A, 109, pp.2736~2741 (2012)[DOI]
- Jin K, "HOXB7 Is an ERalpha cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance", Cancer Discov, 5, pp.944~959 (2015)[DOI]
- Shah N, "HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERalpha and inducing IL-6 expression", Cancer Res, 73, pp.5449~5458 (2013)[DOI]
- Barber BA, "Epigenetic control of Hox genes during neurogenesis, development, and disease", Ann Anat, 192, pp.261~274 (2010)[DOI]
- Srivastava S, "Epigenetic mechanisms and boundaries in the regulation of mammalian Hox clusters", Mech Deve, 138, pp.160~169 (2015)[DOI]
- Daftary GS, "Endocrine regulation of HOX genes", Endocr Rev, 27, pp.331~355 (2006)[DOI]
- Cakmak H, "Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions", Semin Reprod Med, 28, pp.69~74 (2010)[DOI]
- Iorio MV, "Breast cancer and microRNAs: therapeutic impact", Breast, 20(Suppl 3), pp.S63~S70 (2011)
- Xin F, "Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance", Bioinformatics, 25, pp.430~434 (2009)[DOI]
- Hoppe R, "Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptorpositive breast cancer following tamoxifen treatment", Eur J Cancer, 49, pp.3598~3608 (2013)[DOI]
- Jansen MP, "Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer", Cancer Res, 73, pp.6632~6641 (2013)[DOI]
- Nguyen VT, "Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion", Nat Commun, 6, pp.10044~ (2015)[DOI]
- di Pietro M, "Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus", Proc Natl Acad Sci U S A, 109, pp.9077~9082 (2012)[DOI]
- Misteli T, "Higher-order genome organization in human disease", Cold Spring Harb Perspect Biol, 2, pp.a000794~ (2010)
- Deng C, "HoxBlinc RNA recruits Set1", MLL complexes to activate Hox gene expression patterns and mesoderm lineage development, 2016, pp.14, 103~114
